NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Interventional procedure consultation document

Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting

The arteries in the neck that supply the brain can become narrowed by fatty deposits. Fragments of these fatty deposits can detach and block smaller arteries that supply blood to parts of the brain, causing a stroke or a ‘mini stroke’ (transient ischaemic attack; TIA). A stent can be used to open up the narrowed arteries but there is a risk that it may dislodge fatty deposits and cause a TIA or a stroke.

Transcervical extracorporeal reverse flow neuroprotection aims to reduce the risk of stroke by redirecting blood away from the brain into a filtering system outside the body. This removes any fragments that might detach while the stent is placed. The neuroprotection system is inserted through a small cut in the neck.

The National Institute for Health and Care Excellence (NICE) is examining transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting and will publish guidance on its safety and efficacy to the NHS. NICE’s Interventional Procedures Advisory Committee has considered the available evidence and the views of specialist advisers, who are consultants with knowledge of the procedure. The Advisory Committee has made draft recommendations about transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting.

This document summarises the procedure and sets out the draft recommendations made by the Advisory Committee. It has been prepared for public consultation. The Advisory Committee particularly welcomes:

- comments on the draft recommendations
- the identification of factual inaccuracies
- additional relevant evidence, with bibliographic references where possible.

Note that this document is not NICE’s formal guidance on this procedure. The recommendations are provisional and may change after consultation.
The process that NICE will follow after the consultation period ends is as follows.

- The Advisory Committee will meet again to consider the original evidence and its draft recommendations in the light of the comments received during consultation.
- The Advisory Committee will then prepare draft guidance which will be the basis for NICE’s guidance on the use of the procedure in the NHS.

For further details, see the [Interventional Procedures Programme process guide](#), which is available from the NICE website.

Through its guidance NICE is committed to promoting race and disability equality, equality between men and women, and to eliminating all forms of discrimination. One of the ways we do this is by trying to involve as wide a range of people and interest groups as possible in the development of our interventional procedures guidance. In particular, we aim to encourage people and organisations from groups who might not normally comment on our guidance to do so.

In order to help us promote equality through our guidance, we should be grateful if you would consider the following question:

Are there any issues that require special attention in light of NICE’s duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations between people with a characteristic protected by the equalities legislation and others?

Please note that NICE reserves the right to summarise and edit comments received during consultations or not to publish them at all where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would otherwise be inappropriate.

Closing date for comments: 18 March 2016

Target date for publication of guidance: June 2016

## 1 Draft recommendations

1.1 Current evidence on the safety of transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting shows well-documented risks. The evidence on efficacy is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.
1.2 Patient selection should be carried out by a multidisciplinary team, which should include an interventional radiologist or a neuroradiologist, a vascular surgeon and a physician with a specialist interest in stroke.

1.3 This procedure should only be carried out by clinicians with specific training and expertise in the technique who regularly perform complex endovascular interventions.

2 Indications and current treatments

2.1 Narrowing of the carotid arteries by atherosclerosis may lead to transient ischaemic attack or stroke. Treatment includes managing cardiovascular risk factors (stopping smoking, taking antithrombotic medication and statins). In some people, surgical revascularisation (carotid endarterectomy) or carotid artery angioplasty and stenting may be considered. Debris dislodged during carotid artery stenting can embolise to the cerebral circulation and cause a transient ischaemic attack or stroke.

2.2 The risk of an embolic stroke during carotid artery stenting can be reduced either by using filters to capture any embolic debris (distal neuroprotection) or by temporarily reversing the blood flow through the stenotic lesion and away from the brain by blocking the flow in the carotid artery (proximal neuroprotection).

2.3 Neuroprotection devices may be introduced via the femoral or carotid artery.

3 The procedure

3.1 Transcervical extracorporeal reverse flow neuroprotection is an approach to providing proximal neuroprotection during carotid artery angioplasty and stenting. By directly accessing the carotid artery, it aims to avoid the risks of endovascular manipulation within
the aortic arch that occur with a transfemoral approach, and make access possible if there is unfavourable aortic arch anatomy or iliac artery disease.

3.2 With the patient under local, regional or general anaesthesia, a small incision is made in the neck and a catheter introduced into the common carotid artery. A catheter is then placed in the femoral or jugular vein. The common carotid artery is temporarily blocked and retrograde flow is established through the stenosis in the internal carotid artery. The blood is passed through a filtering system outside the body to remove any dislodged debris. It is then returned through the femoral or jugular vein. Once blood flow is reversed, carotid artery angioplasty and stenting are done. After the stent has been successfully placed, normal blood flow to the brain is allowed to resume and the catheters are removed.

4 Efficacy

This section describes efficacy outcomes from the published literature that the Committee considered as part of the evidence about this procedure. For more detailed information on the evidence, see the interventional procedure overview [add URL].

4.1 In a comparative study of 64 patients treated by transcervical carotid artery stenting with flow reversal (n=31) or transfemoral carotid artery stenting with distal filter protection (n=33), there were no reports of stroke after stenting in either group. In a comparative study of 55 patients treated by transcervical carotid artery stenting with flow reversal or transfemoral carotid artery stenting with distal filter protection, 6% (2/31) of patients had a transient ischaemic attack (TIA) and none had a stroke in the transcervical carotid artery stenting group with flow reversal. In the transfemoral carotid artery stenting group, 4% (1/24) of patients had a TIA and 4% (1/24) had a stroke (timing not reported). In a prospective case
series of 212 patients treated by transcervical carotid artery stenting with flow reversal, stroke occurred in 2% (4/212) of patients within 30 days of the procedure; there was 1 transient ischaemic attack and 3 major strokes.

4.2 In the comparative study of 64 patients treated by transcervical carotid artery stenting or transfemoral carotid artery stenting, there were no significant changes in the Rankin stroke scale after the procedure in either group.

4.3 In the same study of 64 patients, asymptomatic new ischaemic cerebral lesions were diagnosed on diffusion-weighted MRI in 13% (4/31) of patients in the transcervical group compared against 33% (11/33) in the transfemoral group (p=0.03). In a case series of 48 patients treated by transcervical carotid artery stenting with flow reversal, there were 16 new ischaemic lesions (diagnosed on diffusion-weighted MRI 3 days after the procedure) in 14% (6/43) of patients (mean of 2.7 lesions per patient, range 2–4). All lesions were ipsilateral to the operated carotid artery. In 4 out of 6 patients, the new lesions remained asymptomatic.

4.4 In a case series of 97 patients treated by transcervical carotid artery stenting with flow reversal, 3% (3/103) of procedures were converted to endarterectomy. The reasons for the conversions were common carotid dissection with the entry sheath, inability to cross the lesion in the internal carotid artery with the guidewire and severe agitation in 1 patient who needed conversion to general anaesthesia.

4.5 In a comparative study of 81 patients treated by transcervical carotid artery stenting with flow reversal (n=36) or carotid endarterectomy (n=45), there were high-intensity transient signals during the procedure in 3% (1/36) of patients treated by transcervical carotid artery stenting (not reported for the carotid
endarterectomy group). In a prospective case series of 62 patients treated by transcervical carotid artery stenting with flow reversal, there were perioperative high-intensity transient signals reported in 6% (2/62) of patients.

4.6 In the comparative study of 81 patients treated by transcervical carotid artery stenting or carotid endarterectomy, there was an increase in mean cerebral artery flow velocity (measured by transcranial Doppler) after completion of the procedure in 100% (36/36) of patients treated by transcervical carotid artery stenting.

In the prospective case series of 62 patients treated by transcervical carotid artery stenting with flow reversal, there was a significant improvement in the middle cerebral artery mean flow velocity and pulsatility index on completion of the procedure.

4.7 The specialist advisers listed the following key efficacy outcomes: reduced incidence of clinical neuroembolic events and a decreased rate of new ischaemic lesions on brain MRI post-procedure (a surrogate marker).

5 Safety

This section describes safety outcomes from the published literature that the Committee considered as part of the evidence about this procedure. For more detailed information on the evidence, see the interventional procedure overview [add URL].

5.1 Death from myocardial infarction 48 hours after the procedure was reported in 1 patient in a prospective case series of 212 patients treated by transcervical carotid artery stenting with flow reversal. Death was reported in 2 patients in a case series of 141 patients treated by transcervical carotid artery stenting with extracorporeal reverse flow neuroprotection. One patient died from respiratory failure within 30 days of the procedure and another patient died
from myocardial infarction 15 days after the procedure after readmission with pneumonia and diabetic ketoacidosis.

5.2 Transient intolerance to flow reversal was reported in 1 patient treated by transcervical carotid artery stenting in a comparative study of 81 patients treated by transcervical carotid artery stenting (n=36) or carotid endarterectomy (n=45). Clamping of the common carotid was then only maintained during the key steps of the procedure. Intolerance to flow reversal was reported in 1% (3/219) of procedures in the case series of 212 patients; this was treated by declamping the common carotid artery and rapidly completing the procedure.

5.3 Major dissection of the common carotid artery was reported in 1 patient treated by transcervical carotid artery stenting in the comparative study of 81 patients. This was treated by a bypass from the common carotid artery to the distal internal carotid artery. Arterial dissection was reported in 6% (8/141) of patients in the case series of 141 patients. For 5 dissections, no treatment was needed; they were at the site of the arterial sheath or between the sheath and the carotid bifurcation. For the 3 dissections that needed treatment, 1 procedure was converted to carotid endarterectomy at the index procedure, 1 needed the placement of a second stent during the original procedure and 1 was repaired surgically during the original procedure. One of the patients with a dissection had a minor ipsilateral stroke 8 hours after the procedure. This was judged to be unrelated to the dissection because the second stent had adequately managed the intimal flap.

5.4 Severe spasm of the distal carotid artery was reported in 1 patient treated by transcervical carotid artery stenting in the comparative study of 81 patients. Significant distal internal carotid spasm was reported in 2% (4/212) of patients in the case series of...
212 patients; this was treated with intra-arterial nitroglycerin in 1 patient and it resolved spontaneously after guidewire withdrawal in 3 patients. Significant distal internal carotid spasm was reported in 2 patients in a case series of 62 patients treated by transcervical carotid artery stenting with flow reversal; this was treated with intra-arterial nitroglycerin. Distal internal carotid artery spasm was reported in 13% (6/48) of patients in a case series of 48 patients treated by carotid artery stenting with flow reversal. This was treated with intra-arterial nitroglycerin.

5.5 Bradycardia and hypotension related to balloon inflation was reported in 6% (2/36) of patients treated by transcervical carotid artery stenting in the comparative study of 81 patients. This was successfully treated with atropine. Bradycardia was reported in 13% (4/31) of patients in the transcervical carotid artery stenting with flow reversal group and in none of the patients in the transfemoral carotid artery stenting group with distal filter neuroprotection (n=24) in a comparative study of 55 patients.

5.6 Extensive cerebral haematoma was reported in 1 patient in the case series of 62 patients; this was identified on a CT scan after the patient returned with hemiplegia and aphasia after an episode of intense headache 48 hours after hospital discharge. It was treated by surgical drainage.

5.7 Transient laryngeal nerve palsy was reported in 1% (2/212) of patients in the case series of 212 patients; this was secondary to impregnation of the nerve with local anaesthesia. Cranial nerve injury affecting the tenth nerve was reported in 1 patient in the case series of 141 patients; this caused hoarseness, which fully resolved at 6 months.

5.8 Cervical haematoma was reported in 6% (2/31) of patients treated by transcervical carotid artery stenting in the comparative study of
55 patients; one of the 2 patients was treated by surgical drainage and had no neurological sequelae. Cervical haematoma was reported in 1 patient in the case series of 212 patients; this was treated by surgical drainage.

5.9 In addition to safety outcomes reported in the literature, specialist advisers are asked about anecdotal adverse events (events which they have heard about) and about theoretical adverse events (events which they think might possibly occur, even if they have never done so). For this procedure, specialist advisers did not list any anecdotal adverse events. They considered that the following were theoretical adverse events: false aneurysm at the site of puncture, potential risk to the brain of reversing the flow in the internal carotid artery for the duration of the procedure and potential risk of re-establishing antegrade flow (reperfusion injury).

6 Further information

6.1 The committee noted that NICE has issued interventional procedure guidance about carotid artery stenting in symptomatic and asymptomatic patients.

6.2 For related NICE guidance, see the NICE website.

Tom Clutton-Brock
Chairman, Interventional Procedures Advisory Committee
February, 2016